EUVIMEDEUVIMED entdecken
Crossref

Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia

Li-Wen Chang, Shian-Shiang Wang, Cheng-Kuang Yang, Kevin Lu, Chuan-Shu Chen, Chen-Li Cheng, Sheng-Chun Hung, Kun-Yuan Chiu, Chiann Yi Hsu, Jian-Ri Li

Anticancer Research · 2023

DOI: 10.21873/anticanres.16185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Li-Wen Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. Hauptthemen laut MEDLINE: 5-alpha Reductase Inhibitors, Prostatic Hyperplasia, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5-alpha Reductase InhibitorsProstatic HyperplasiaProstatic NeoplasmsHumansMaleEnzyme InhibitorsHyperplasiaOxidoreductasesProstateProstate-Specific AntigenRetrospective StudiesRisk Assessment

Stichwörter der Autor:innen

Alpha blockerbenign prostate hyperplasiafive-alpha reductase inhibitorprostate cancerprostate specific antigen

Substanzen

5-alpha Reductase InhibitorsEnzyme InhibitorsOxidoreductasesProstate-Specific Antigen

Autor:innen und Institutionen

  • Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
  • Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, R.O.C.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; fisherfishli@yahoo.com.tw.
  • Division of Surgical Intensive Care Unit, Department of Intensive Care, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.

Zitieren

APA

Chang, L. W., Wang, S. S., Yang, C. K., Lu, K., Chen, C. S., Cheng, C. L., Hung, S. C., Chiu, K. Y., Hsu, C. Y., & Li, J. R. (2023). Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia. Anticancer Research. https://doi.org/10.21873/anticanres.16185

Vancouver

Chang LW, Wang SS, Yang CK, Lu K, Chen CS, Cheng CL, et al. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia. Anticancer Research. 2023. doi:10.21873/anticanres.16185

BibTeX
@article{Chang2023,
  author = {Chang, Li-Wen and Wang, Shian-Shiang and Yang, Cheng-Kuang and Lu, Kevin and Chen, Chuan-Shu and Cheng, Chen-Li and Hung, Sheng-Chun and Chiu, Kun-Yuan and Hsu, Chiann Yi and Li, Jian-Ri},
  title = {Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16185}
}
Kostenlos starten →